These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 19121944

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Ponalrestat: a potent and specific inhibitor of aldose reductase.
    Ward WH, Sennitt CM, Ross H, Dingle A, Timms D, Mirrlees DJ, Tuffin DP.
    Biochem Pharmacol; 1990 Jan 15; 39(2):337-46. PubMed ID: 2105733
    [Abstract] [Full Text] [Related]

  • 8. Effect of C7 modifications on benzothiadiazine-1,1-dioxide derivatives on their inhibitory activity and selectivity toward aldose reductase.
    Zhang S, Chen X, Parveen S, Hussain S, Yang Y, Jing C, Zhu C.
    ChemMedChem; 2013 Apr 15; 8(4):603-13. PubMed ID: 23136050
    [Abstract] [Full Text] [Related]

  • 9. Hydrogen bonding interactions between aldose reductase complexed with NADP(H) and inhibitor tolrestat studied by molecular dynamics simulations and binding assay.
    Lee YS, Hodoscek M, Kador PF, Sugiyama K.
    Chem Biol Interact; 2003 Feb 01; 143-144():307-16. PubMed ID: 12604217
    [Abstract] [Full Text] [Related]

  • 10. Aldehyde and aldose reductases from human placenta. Heterogeneous expression of multiple enzyme forms.
    Vander Jagt DL, Hunsaker LA, Robinson B, Stangebye LA, Deck LM.
    J Biol Chem; 1990 Jul 05; 265(19):10912-8. PubMed ID: 2113526
    [Abstract] [Full Text] [Related]

  • 11. Aldose and aldehyde reductases: correlation of molecular modeling and mass spectrometric studies on the binding of inhibitors to the active site.
    El-Kabbani O, Rogniaux H, Barth P, Chung RP, Fletcher EV, Van Dorsselaer A, Podjarny A.
    Proteins; 2000 Nov 15; 41(3):407-14. PubMed ID: 11025551
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Probing the ultra-high resolution structure of aldose reductase with molecular modelling and noncovalent mass spectrometry.
    Darmanin C, Chevreux G, Potier N, Van Dorsselaer A, Hazemann I, Podjarny A, El-Kabbani O.
    Bioorg Med Chem; 2004 Jul 15; 12(14):3797-806. PubMed ID: 15210146
    [Abstract] [Full Text] [Related]

  • 14. X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.
    Ruiz FX, Cousido-Siah A, Mitschler A, Farrés J, Parés X, Podjarny A.
    Chem Biol Interact; 2013 Feb 25; 202(1-3):178-85. PubMed ID: 23295227
    [Abstract] [Full Text] [Related]

  • 15. A 'specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil.
    Urzhumtsev A, Tête-Favier F, Mitschler A, Barbanton J, Barth P, Urzhumtseva L, Biellmann JF, Podjarny A, Moras D.
    Structure; 1997 May 15; 5(5):601-12. PubMed ID: 9195881
    [Abstract] [Full Text] [Related]

  • 16. Factorizing selectivity determinants of inhibitor binding toward aldose and aldehyde reductases: structural and thermodynamic properties of the aldose reductase mutant Leu300Pro-fidarestat complex.
    Petrova T, Steuber H, Hazemann I, Cousido-Siah A, Mitschler A, Chung R, Oka M, Klebe G, El-Kabbani O, Joachimiak A, Podjarny A.
    J Med Chem; 2005 Sep 08; 48(18):5659-65. PubMed ID: 16134934
    [Abstract] [Full Text] [Related]

  • 17. Structure based comprehensive modelling, spatial fingerprints mapping and ADME screening of curcumin analogues as novel ALR2 inhibitors.
    Verma SK, Thareja S.
    PLoS One; 2017 Sep 08; 12(4):e0175318. PubMed ID: 28399135
    [Abstract] [Full Text] [Related]

  • 18. Benzoxazinone-thiosemicarbazones as antidiabetic leads via aldose reductase inhibition: Synthesis, biological screening and molecular docking study.
    Shehzad MT, Imran A, Njateng GSS, Hameed A, Islam M, Al-Rashida M, Uroos M, Asari A, Shafiq Z, Iqbal J.
    Bioorg Chem; 2019 Jun 08; 87():857-866. PubMed ID: 30551808
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Inhibition kinetics of human kidney aldose and aldehyde reductases by aldose reductase inhibitors.
    Bhatnagar A, Liu SQ, Das B, Ansari NH, Srivastava SK.
    Biochem Pharmacol; 1990 Mar 15; 39(6):1115-24. PubMed ID: 2157439
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.